Coherus BioSciences Inc (CHRS)vsBeiGene, Ltd. (ONC)
CHRS
Coherus BioSciences Inc
$1.41
-2.08%
HEALTHCARE · Cap: $220.58M
ONC
BeiGene, Ltd.
$327.21
-0.98%
HEALTHCARE · Cap: $34.29B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 12142% more annual revenue ($5.74B vs $46.88M). CHRS leads profitability with a 397.3% profit margin vs 8.9%. ONC earns a higher WallStSmart Score of 54/100 (C-).
CHRS
Hold49
out of 100
Grade: D+
ONC
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CHRS.
Margin of Safety
+81.1%
Fair Value
$1857.02
Current Price
$327.21
$1529.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 397 of every $100 in revenue as profit
Revenue surging 62.0% year-over-year
Reasonable price relative to book value
Revenue surging 35.5% year-over-year
Earnings expanding 16971.0% YoY
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of -192.9% — below average capital efficiency
Earnings declined 75.5%
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CHRS
The strongest argument for CHRS centers on Profit Margin, Revenue Growth, Price/Book. Profitability is solid with margins at 397.3% and operating margin at -293.7%. Revenue growth of 62.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 35.5% demonstrates continued momentum.
Bear Case : CHRS
The primary concerns for CHRS are Market Cap, Return on Equity, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 74.6x leaves little room for execution misses.
Key Dynamics to Monitor
CHRS profiles as a growth stock while ONC is a hypergrowth play — different risk/reward profiles.
CHRS carries more volatility with a beta of 0.98 — expect wider price swings.
CHRS is growing revenue faster at 62.0% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (54/100 vs 49/100) and 35.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coherus BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?